Steady investments in drug discovery are critical for drug development and for bringing treatments to patients that need them. Over the past ten years investments in treatments for pain have been inconsistent. Several factors influence the lack of investments into treatments for pain and addiction including uncertainty in both coverage and access of treatments and regulatory requirements. Modernization of drug development processes, increased engagement between the FDA and industry sponsors, and incentives for the development of new therapies will help mitigate some of these issues. Panelists will discuss solutions and policies to address the regulatory requirements in the effort to enhance the research & development ecosystem for pain and addiction treatments.

Session ID: 361810